Media Release
Juni 3, 2024
Perseo pharma and Nestlé Health Science present the compelling preclinical data on PER301 for Exocrine Pancreatic Insufficiency at the DDW (Digestive Disease Week) conference in Washington on May 21, 2024.
Juni 3, 2024
Following a fruitful first phase of partnership started in 2022, Perseo pharma and Nestlé Health Science are strengthening their collaboration focused on the innovative pancreatic enzyme replacement therapy (PER301) they have been jointly developing. Data on solid dosing in the animal model will be acquired in this next step.
July 7, 2022
Perseo pharma announces strategic collaboration with Nestlé Health Science to develop novel therapies for digestive diseases
Muttenz, Switzerland – Perseo pharma, a preclinical stage biopharmaceutical company focused on breaking new ground in enzyme therapies, announced today that it has entered a strategic research and development collaboration with Nestlé Health Science S.A. to develop up to three programs targeting enzyme deficiencies in patients suffering from digestive diseases.
“We are incredibly excited to enter into a collaboration with Nestlé Health Science, a leader in the field of nutritional science. This collaboration reinforces our quest to find a novel way to treat digestive diseases” said Dr. Yves Dudal, CEO Perseo pharma. “Pairing our capabilities in developing innovative oral enzyme digestive therapies with Nestle Health Science’s commitment in this area will potentially bring meaningful and life-changing options to patients.”
“Our collaboration with Perseo pharma has the potential to ease the burden of current therapies for patients with digestive enzyme deficiencies,” said Hans-Juergen Woerle, Chief Scientific and Medical Officer for Nestlé Health Science. “We are looking forward to working together to develop innovative solutions.”